Evidence map›Paper›PMID 40626322›Full record

ArticleMedComm2025

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells.

Michaël Constantinides, Loïs Coënon, Paolo Falvo, Caroline Multrier, Davide Lombardi, Francesco Bertolini, Pierre Martineau, Bruno Robert, Guillaume Cartron, Martin Villalba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michaël ConstantinidesIRMB, University of Montpellier INSERM CHU Montpellier Montpellier France.
Loïs CoënonIRMB, University of Montpellier INSERM CHU Montpellier Montpellier France.
Paolo FalvoLaboratory of Hematology-Oncology IRCCS European Institute of Oncology Milan Italy.
Caroline MultrierIRMB, University of Montpellier INSERM CHU Montpellier Montpellier France.
Davide LombardiLaboratory of Hematology-Oncology IRCCS European Institute of Oncology Milan Italy.
Francesco BertoliniLaboratory of Hematology-Oncology IRCCS European Institute of Oncology Milan Italy.
Pierre MartineauIRCM, University of Montpellier INSERM, ICM Montpellier France.
Bruno RobertIRCM, University of Montpellier INSERM, ICM Montpellier France.
Guillaume CartronDepartment of Clinical Hematology CHU Montpellier Montpellier France.
Martin VillalbaIRMB, University of Montpellier INSERM CHU Montpellier Montpellier France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADCCB‐cell chronic lymphocytic leukemiaengineered mAbsNK cell therapynon‐Hodgkin lymphoma

Identifiers

PMID40626322
PMCPMC12231191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.